This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Phase 3 Evaluation of BMS-790052 (Daclatasvir) C...
Clinical trial

A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C + Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated 23-Nov-

Read time: 1 mins
Last updated:14th Feb 2012
To compare rates of SVR12, defined as HCV RNA < LOQ (detectable or undetectable) at follow-up Week 12, for genotype 1 patients treated with either BMS-790052 or TVR in combination with pegIFN?-2a/RBV
Category Value
Study start date 2012-02-14

View full details